Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | BRD4 | O60885 | 4/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.48 |
| ▸ | STAT6 | P42226 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.44 |
| ▸ | JAK2 | O60674 | 4/20 | 0.43 |
| ▸ | JAK3 | P52333 | 3/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.42 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13756809 | 0.88 | LRRK2 (0.53) | PTK2STAT6LRRK2JAK2JAK3 | |
| SCHEMBL13756882 | 0.86 | STAT6 (0.53) | EGFRSTAT6MAPTALDH1A1LMNA | |
| SCHEMBL13756770 | 0.84 | PTK2 (0.48) | EGFRBRD4PTK2STAT6LRRK2 | |
| SCHEMBL4287793 | 0.81 | BRD4 (0.55) | EGFRBRD4PTK2STAT6LRRK2 | |
| SCHEMBL13756780 | 0.79 | LRRK2 (0.49) | LRRK2JAK2PKMYT1 | |
| SCHEMBL13756776 | 0.79 | PDGFRB (0.52) | JAK2SRCKMT2A | |
| SCHEMBL13756842 | 0.79 | NUAK1 (0.45) | PTK2STAT6LRRK2JAK2JAK3 | |
| SCHEMBL13756706 | 0.77 | BRD4 (0.44) | BRD4PTK2JAK2ALDH1A1 | |
| SCHEMBL13756806 | 0.76 | STAT6 (0.58) | EGFRSTAT6JAK2MAPT | |
| SCHEMBL13756873 | 0.76 | BRD4 (0.52) | EGFRBRD4PTK2JAK2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | EGFR 109/4885BRD4 964/4885PTK2 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.